Does the media prefer NVO or JNJ?

In the previous week, Johnson & Johnson had 17 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 50 mentions for Johnson & Johnson and 33 mentions for Novo Nordisk A/S. Johnson & Johnson's average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.58 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Johnson & Johnson 38 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NVO or MRK?

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.36 $15.51B $4.09 11.18 Merck & Co., Inc. $65.01B 5.14 $18.25B $1.25 108.27

Does the media refer more to NVO or MRK?

In the previous week, Merck & Co., Inc. had 12 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 45 mentions for Merck & Co., Inc. and 33 mentions for Novo Nordisk A/S. Merck & Co., Inc.'s average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.58 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Merck & Co., Inc. 30 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% Novo Nordisk A/S 35.36% 61.20% 21.49%

Does the media favor NVS or NVO?

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 12 mentions for Novartis. Novartis' average media sentiment score of 1.00 beat Novo Nordisk A/S's score of 0.58 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media prefer AZN or NVO?

In the previous week, Novo Nordisk A/S had 22 more articles in the media than Astrazeneca. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 11 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.58 beat Astrazeneca's score of 0.29 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Novo Nordisk A/S 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive

Which has higher valuation & earnings, NVO or PFE?

Novo Nordisk A/S has higher earnings, but lower revenue than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.36 $15.51B $4.09 11.18 Pfizer $62.58B 2.49 $7.77B $0.76 35.91

Is NVO or PFE more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 61.20% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 61.20% 21.49% Pfizer 6.80% 19.63% 8.46%

Does the media refer more to NVO or PFE?

In the previous week, Pfizer had 29 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 62 mentions for Pfizer and 33 mentions for Novo Nordisk A/S. Pfizer's average media sentiment score of 1.09 beat Novo Nordisk A/S's score of 0.58 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Pfizer 38 Very Positive mention(s) 11 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Novo Nordisk A/S (NVO) Competitors

$45.71 +0.83 (+1.85%)

Closing price 03:59 PM Eastern

Extended Trading

$45.74 +0.03 (+0.06%)

As of 07:59 PM Eastern

Compare

NVO vs. JNJ, MRK, NVS, AZN, and PFE

Should you buy Novo Nordisk A/S stock or one of its competitors? Novo Nordisk A/S's main competitors and comparable companies include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Novo Nordisk A/S compare to Johnson & Johnson?

Novo Nordisk A/S (NYSE:NVO) and Johnson & Johnson (NYSE:JNJ) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Novo Nordisk A/S has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.36	$15.51B	$4.09	11.18
Johnson & Johnson	$94.19B	6.93	$26.80B	$8.63	31.41

In the previous week, Johnson & Johnson had 17 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 50 mentions for Johnson & Johnson and 33 mentions for Novo Nordisk A/S. Johnson & Johnson's average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.58 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive
Johnson & Johnson	38 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S presently has a consensus target price of $64.94, suggesting a potential upside of 42.06%. Johnson & Johnson has a consensus target price of $268.22, suggesting a potential downside of 1.04%. Given Novo Nordisk A/S's higher probable upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	16 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

Novo Nordisk A/S has a net margin of 35.36% compared to Johnson & Johnson's net margin of 21.48%. Novo Nordisk A/S's return on equity of 61.20% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Johnson & Johnson	21.48%	32.42%	13.35%

Summary

Johnson & Johnson beats Novo Nordisk A/S on 13 of the 20 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Novo Nordisk A/S (NYSE:NVO) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Novo Nordisk A/S currently has a consensus price target of $64.94, suggesting a potential upside of 42.06%. Merck & Co., Inc. has a consensus price target of $135.50, suggesting a potential upside of 0.12%. Given Novo Nordisk A/S's higher probable upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	16 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.68

In the previous week, Merck & Co., Inc. had 12 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 45 mentions for Merck & Co., Inc. and 33 mentions for Novo Nordisk A/S. Merck & Co., Inc.'s average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.58 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive
Merck & Co., Inc.	30 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S has a net margin of 35.36% compared to Merck & Co., Inc.'s net margin of 4.77%. Novo Nordisk A/S's return on equity of 61.20% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Merck & Co., Inc.	4.77%	16.73%	6.13%

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.36	$15.51B	$4.09	11.18
Merck & Co., Inc.	$65.01B	5.14	$18.25B	$1.25	108.27

Novo Nordisk A/S has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 11 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.41	$13.98B	$6.63	23.33
Novo Nordisk A/S	$46.80B	4.36	$15.51B	$4.09	11.18

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Novartis pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
Novo Nordisk A/S	35.36%	61.20%	21.49%

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Novartis currently has a consensus target price of $141.20, suggesting a potential downside of 8.73%. Novo Nordisk A/S has a consensus target price of $64.94, suggesting a potential upside of 42.06%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	0 Sell rating(s)	16 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Novartis has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 21 more articles in the media than Novartis. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 12 mentions for Novartis. Novartis' average media sentiment score of 1.00 beat Novo Nordisk A/S's score of 0.58 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Novartis on 10 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Novo Nordisk A/S had 22 more articles in the media than Astrazeneca. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 11 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.58 beat Astrazeneca's score of 0.29 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Novo Nordisk A/S	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has lower revenue, but higher earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.23	$10.23B	$6.69	23.95
Novo Nordisk A/S	$46.80B	4.36	$15.51B	$4.09	11.18

Novo Nordisk A/S has a net margin of 35.36% compared to Astrazeneca's net margin of 17.02%. Novo Nordisk A/S's return on equity of 61.20% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Astrazeneca has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Astrazeneca currently has a consensus target price of $211.00, suggesting a potential upside of 31.69%. Novo Nordisk A/S has a consensus target price of $64.94, suggesting a potential upside of 42.06%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Novo Nordisk A/S	0 Sell rating(s)	16 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Novo Nordisk A/S beats Astrazeneca on 12 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Pfizer?

Novo Nordisk A/S (NYSE:NVO) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Pfizer had 29 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 62 mentions for Pfizer and 33 mentions for Novo Nordisk A/S. Pfizer's average media sentiment score of 1.09 beat Novo Nordisk A/S's score of 0.58 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	15 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive
Pfizer	38 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.3%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novo Nordisk A/S currently has a consensus price target of $64.94, suggesting a potential upside of 42.06%. Pfizer has a consensus price target of $28.28, suggesting a potential upside of 3.60%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	16 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Novo Nordisk A/S has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 61.20% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Pfizer	6.80%	19.63%	8.46%

Novo Nordisk A/S has higher earnings, but lower revenue than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.36	$15.51B	$4.09	11.18
Pfizer	$62.58B	2.49	$7.77B	$0.76	35.91

Summary

Novo Nordisk A/S beats Pfizer on 11 of the 19 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$204.90B	$12.13B	$7.10B	$24.10B
Dividend Yield	3.81%	2.69%	2.56%	3.69%
P/E Ratio	11.41	782.06	270.60	29.90
Price / Sales	4.36	761.34	618.85	91.67
Price / Cash	9.79	15.16	28.88	20.16
Price / Book	6.95	10.49	11.33	4.89
Net Income	$15.51B	$2.81B	$3.46B	$1.07B
7 Day Performance	-3.19%	1.41%	1.13%	-0.60%
1 Month Performance	-9.11%	0.87%	2.62%	1.82%
1 Year Performance	-15.05%	146.12%	62.66%	17.21%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.6423 of 5 stars	$45.71 +1.9%	$64.94 +42.1%	-14.4%	$204.90B	$46.80B	11.18	69,505
JNJ Johnson & Johnson	4.6994 of 5 stars	$259.98 +0.1%	$268.22 +3.2%	+48.5%	$626.48B	$94.19B	30.12	138,200	Trending News Insider Trade Options Volume Gap Up
MRK Merck & Co., Inc.	4.3009 of 5 stars	$132.47 +1.6%	$135.50 +2.3%	+61.3%	$326.59B	$65.01B	105.90	75,000
NVS Novartis	3.4357 of 5 stars	$152.84 -1.1%	$141.20 -7.6%	+22.5%	$291.46B	$54.53B	23.04	75,267
AZN Astrazeneca	4.8797 of 5 stars	$158.03 -0.5%	$211.00 +33.5%	N/A	$245.12B	$58.74B	23.63	96,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Which has more volatility and risk, NVO or JNJ?

Do insiders and institutionals hold more shares of NVO or JNJ?

Is NVO or JNJ a better dividend stock?

Which has better valuation and earnings, NVO or JNJ?

Does the media prefer NVO or JNJ?

Do analysts prefer NVO or JNJ?

Is NVO or JNJ more profitable?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Do analysts recommend NVO or MRK?

Does the media refer more to NVO or MRK?

Is NVO or MRK more profitable?

Is NVO or MRK a better dividend stock?

Do institutionals & insiders believe in NVO or MRK?

Which has higher earnings and valuation, NVO or MRK?

Which has more risk and volatility, NVO or MRK?

Summary

How does Novo Nordisk A/S compare to Novartis?

Which has preferable earnings & valuation, NVS or NVO?

Is NVS or NVO a better dividend stock?

Is NVS or NVO more profitable?

Do insiders & institutionals believe in NVS or NVO?

Do analysts rate NVS or NVO?

Which has more risk & volatility, NVS or NVO?

Does the media favor NVS or NVO?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Does the media prefer AZN or NVO?

Is AZN or NVO a better dividend stock?

Which has better earnings & valuation, AZN or NVO?

Is AZN or NVO more profitable?

Which has more risk & volatility, AZN or NVO?

Do institutionals and insiders believe in AZN or NVO?

Do analysts rate AZN or NVO?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Does the media refer more to NVO or PFE?

Is NVO or PFE a better dividend stock?

Do analysts recommend NVO or PFE?

Which has more volatility & risk, NVO or PFE?

Do institutionals and insiders believe in NVO or PFE?

Is NVO or PFE more profitable?

Which has higher valuation & earnings, NVO or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools